Contracts › 75A50121C00077
75A50121C00077: The Overall Objective of This Contract Is to Advance the Development of Monovalent Vaccines for Prevention of Marburg Virus (MARV) and Sudan Ebolavirus (SUDV) Disease. These Vaccines Are Based on Recombinant Expression of Filovirus Glycoproteins in
Awarded to International Aids Vaccine Initiative Inc. by Office of Assistant Secretary for Preparedness and Response.
$95.6Mobligated
$166.9Mpotential value
31 December 2028current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50121C00077 |
|---|---|
| Awardee | International Aids Vaccine Initiative Inc. |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN42 Health R&D Services; Health Care - Other; Applied Research |
| Place of performance | NY |
| Offers received | 1 |
| Period of performance | 30 September 2021 to 31 December 2028 |
| Potential end | 31 December 2028 |
| Estimated recompete solicitation | ~Q3 2028 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record